Form 4: BridgeBio Pharma CEO Neil Kumar Reports Stock Transactions

CEO Neil Kumar reports the vesting and tax-related disposal of BridgeBio Pharma (BBIO) stock and restricted stock units.

Summary

• On May 16, 2024, Neil Kumar, CEO and President of BridgeBio Pharma, reported transactions involving the company's common stock and restricted stock units (RSUs).
• Kumar acquired 60,667 shares of common stock through the vesting of RSUs.
• He disposed of 30,748 shares to cover tax obligations related to the RSU vesting at a price of $31.04 per share.
• Following these transactions, Kumar directly owns 4,897,443 shares of BridgeBio Pharma common stock.
• Kumar also indirectly owns 1,012,722 shares through the Kumar Haldea Revocable Trust and 995,686 shares through the Kumar Haldea Family Irrevocable Trust, where he serves as a co-trustee.
• The reported transactions also involved the vesting of several tranches of RSUs, specifically 5,130, 2,394, 33,544 and 19,599 RSUs.
• These RSUs vest quarterly, contingent upon Kumar's continued service with the company.

Sentiment

Score: 5

Explanation: This is a routine filing related to executive compensation. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO, trade their company's stock. These filings provide transparency into insider transactions and can be monitored by investors for insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation activities.

Key Dates